Inventor · disambiguated record
Kenneth C. Anderson
Also filed as: ANDERSON KENNETH · ANDERSON KENNETH C · ANDERSON KENNETH CARL
36 granted patents·31 pending applications·144 citations·filing 2001–2022
96Inventor score
Files withDANA FARBER CANCER INST INC29ANDERSON KENNETH C8ACETYLON PHARMACEUTICALS INC5CELGENE INT II SARL3ABBVIE BIOTHERAPEUTICS INC2
Top patents by PatentIndex Score
67 records- 0193US9988343B2Inhibitors of histone deacetylaseDANA FARBER CANCER INST INC·Filed 2014·Granted Jun 5, 2018·7 cites·22 claims
- 0293US8211634B2Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancerDEPINHO RONALD A·Filed 2007·Granted Jul 3, 2012·37 cites·16 claims
- 0390US8999289B2Treatment of protein degradation disordersANDERSON KENNETH C·Filed 2006·Granted Apr 7, 2015·16 cites·32 claims
- 0487US9572854B2Treatment of protein degradation disordersHARVARD COLLEGE·Filed 2015·Granted Feb 21, 2017·6 cites·20 claims
- 0586US9309564B2Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancerDEPINHO RONALD A·Filed 2012·Granted Apr 12, 2016·5 cites·10 claims
- 0685US11337975B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted May 24, 2022·2 cites·5 claims
- 0785US9950047B2XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositionsDANA FARBER CANCER INST INC·Filed 2013·Granted Apr 24, 2018·9 cites·46 claims
- 0885US7070797B2Method of treating hematologic tumors and cancersDANA FARBER CANCER INST INC·Filed 2002·Granted Jul 4, 2006·15 cites·51 claims
- 0983US10172905B1Treatment of protein degradation disordersHARVARD COLLEGE·Filed 2017·Granted Jan 8, 2019·3 cites·20 claims
- 1082US8722724B2Compositions and methods for treating neoplastic diseasesANDERSON KENNETH C·Filed 2008·Granted May 13, 2014·4 cites·9 claims
- 1181US9446146B2Methods and agents for improving targeting of CD138 expressing tumor cellsDAELKEN BENJAMIN·Filed 2008·Granted Sep 20, 2016·10 cites·10 claims
- 1281US8632772B2Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodiesANDERSON KENNETH C·Filed 2007·Granted Jan 21, 2014·7 cites·4 claims
- 1380US11517591B2Immunogenic peptides specific to BCMA and TACI antigensDANA FARBER CANCER INST INC·Filed 2018·Granted Dec 6, 2022·1 cites·38 claims
- 1479US8394816B2Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's MacroglobulinemiaGHOBRIAL IRENE·Filed 2008·Granted Mar 12, 2013·5 cites·38 claims
- 1578US2023210817A1Compositions and methods for treating neoplastic diseasesCELGENE INT II SARL·Filed 2022·Application pending·0 cites
- 1677US9096681B2XBP1, CD138, and CS1 peptidesMUNSHI NIKHIL C·Filed 2009·Granted Aug 4, 2015·2 cites·11 claims
- 1777US7381703B2Aplidine for multiple myeloma treatmentDANA FABER CANCER INST INC·Filed 2004·Granted Jun 3, 2008·12 cites·3 claims
- 1873US12053468B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2022·Granted Aug 6, 2024·0 cites·14 claims
- 1970US10610517B2Compositions and methods for treating neoplastic diseasesCELGENE INT II SARL·Filed 2014·Granted Apr 7, 2020·0 cites·4 claims
- 2070US2009233973A1Epothilone derivatives for the treatment of multiple myelomaLIN BORIS·Filed 2009·Application pending·0 cites
- 2170US2009170862A1Use of c-kit inhibitors for the treatment of myelomaANDERSON KENNETH C·Filed 2009·Application pending·0 cites
- 2269US11465983B2USP7 inhibitors for treating multiple myelomaDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 11, 2022·1 cites·21 claims
- 2369US2023190744A1Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2468US2023248769A1Immunogenic peptides specific to bcma and taci antigens for treatment of cancerDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 2567US8466147B2Use of reversine and analogs for treatment of cancerANDERSON KENNETH C·Filed 2007·Granted Jun 18, 2013·2 cites·28 claims
- 2667US2020206190A1Compositions and methods for treating neoplastic diseasesCELGENE INT II SARL·Filed 2020·Application pending·0 cites
- 2766US2020323849A1Combinations of histone deacetylase inhibitors and immunomodulatory drugsACETYLON PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2866US2022031821A1Xbp1, cd138, and cs1 peptidesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2964US2021170004A1Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositionsDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 3063US11497746B2Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2017·Granted Nov 15, 2022·0 cites·3 claims
- 3163USRE49240EInhibitors of histone deacetylaseMASSACHUSETTS GEN HOSPITAL·Filed 2014·Granted Oct 11, 2022·0 cites·22 claims
- 3261US2023265070A1Novel usp7 inhibitors for treating multiple myelomaDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 3361US2025066738A1Induced pluripotent stem cells (ipsc), t-cell compositions and methods of useDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 3460US2006183793A1Method of treating hematologic tumors and cancersPARDEE ARTHUR B·Filed 2005·Application pending·0 cites
- 3559US11083783B2XBP1, CD138, and CS1 peptidesDANA FARBER CANCER INST INC·Filed 2015·Granted Aug 10, 2021·0 cites·24 claims
- 3659US2024285740A1Compositions and methods for treating cancerDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 3758US2009286823A1CCR1 Inhibitors useful for the treatment of multiple myeloma and other disordersMILLENNIUM PHARM INC·Filed 2008·Application pending·0 cites
- 3858US2006094766A1Epothilone derivatives for the treatment of multiple myelomaLIN BORIS·Filed 2003·Application pending·0 cites
- 3957US9248124B2Use of inhibitors of IκB kinase for the treatment of cancerADAMS JULIAN·Filed 2002·Granted Feb 2, 2016·0 cites·4 claims
- 4057US2013274142A1Cell Co-Culture Systems and Uses ThereofDANA FARBER CANCER INST INC·Filed 2013·Application pending·0 cites
- 4157US2014322201A1Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 4257US2019011433A1Cell co-culture systems and uses thereofDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 4357US2015105358A1Combinations of histone deacetylase inhibitors and immunomodulatory drugsQUAYLE STEVEN NORMAN·Filed 2014·Application pending·0 cites
- 4456US2007225350A1Compositions and methods for treating neoplastic diseasesANDERSON KENNETH C·Filed 2005·Application pending·0 cites
- 4554US12109266B2Modulating gabarap to modulate immunogenic cell deathDANA FARBER CANCER INST INC·Filed 2021·Granted Oct 8, 2024·0 cites·10 claims
- 4654US2010255999A1Cell Co-Culture Systems and Uses ThereofDANA FARBER CANCER INST INC·Filed 2008·Application pending·0 cites
- 4753US8026230B2Methods and compositions for treating cancer using proteasome inhibitorsDANA FARBER CANCER INST INC·Filed 2005·Granted Sep 27, 2011·0 cites·18 claims
- 4853US2024216354A1Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 4952US12448429B2T cell receptors specific to b-cell maturation antigen for treatment of cancerDANA FARBER CANCER INST INC·Filed 2020·Granted Oct 21, 2025·0 cites·11 claims
- 5051US2006166947A1Multiple myeloma treatmentsANDERSON KENNETH C·Filed 2005·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kenneth C. Anderson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →